Although this therapy may be a promising alternative treatment for refractory pituitary adenomas and pituitary carcinomas, the effects of anti-VEGF agents on the pituitary gland are not yet well understood. The gene discussed is VEGFA; the disease is pituitary adenocarcinoma.